Polypeptide With Localisation/Targeting Motif TRIZ Cases

Engineered M, O, and L polypeptide domains enable self-assembled cargo carriers that recruit ESCRT for membrane scission and cell release.

Dual-target CAR-T cells combine CD19 and humanized CD37 recognition to limit antigen-loss relapse and sustain killing in hematological cancers.

A Cas9 nickase and reverse transcriptase system targets PAH mutations with precise sequence edits to restore enzyme function in PKU.

Dual BAFF-R/CD19 CAR-T cells address CD19 antigen loss relapse by recognizing multiple B-cell malignancy targets with one receptor.

Engineered GPC3-binding CAR and TCR domains help T cells overcome tumor immune evasion and kill hepatocellular carcinoma cells.

Stimulatory RNA added to CAR T therapy activates dendritic cells, macrophages, and T cells to improve tumor infiltration and reduce growth.

By integrating an IFN-γ receptor into CAR signaling, macrophages stay in the M1 antitumor state longer and better reshape the tumor microenvironment.

Epitope-segmented EGFRvIII binders improve tumor selectivity while avoiding wild-type EGFR cross-reactivity and normal-tissue toxicity.

Acid-stable S8 proteases stay active in the stomach to improve soybean meal protein digestion, ileal nitrogen digestibility, and animal growth.

AAV-piggyBac vectors integrate therapeutic OTC or MUT1 genes to sustain liver enzyme expression in dividing cells and reduce repeat treatment.

A BBB-penetrating peptide binds α-synuclein and drives proteasomal degradation to reduce aggregation, propagation, and neuronal damage.

Engineered meganucleases target HBV recognition sequences to boost on-target genome cleavage while reducing off-target cutting in host cells.

Surface Strep-tag on attenuated Salmonella enables targeted tumor delivery of anti-cancer and imaging agents while improving strain stability.

Dual BCMA and CD19 targeting in a single CAR enables deeper B cell depletion to support sustained remission in autoimmune disease and cancer.

Optimized CDR sequences improve GPRC5D binding affinity and specificity, enabling stronger tumor cell killing and T cell activation.

FGFR4-targeting antibodies and conjugates block tumor growth and metastasis in FGFR4-positive cancers, enabling more selective treatment.

Gas-permeable culture surfaces and low starting cell density raise T-cell expansion rates while shortening complex cell therapy production.

Engineered cytokine receptors let Treg cells use alternative cytokines to trigger IL-2 signaling, improving persistence while avoiding exogenous IL-2.

Alternative CasP6 nucleases and guide RNAs improve sequence-specific nucleic acid detection and site-specific modification with greater precision.

BCMA-binding antibody fragments enable CAR-modified cells to target chemoresistant multiple myeloma and improve relapse-prone treatment response.

Targeted CRISPR-guided mutagenesis edits cytoplasmic viral DNA despite large, repetitive genomes, improving viral evolution for therapy and vaccine R&D.

Optimized CDR sequences improve ROR1 binding selectivity and therapeutic efficacy, enabling stronger cancer cell killing and reduced metastasis.

An IL-21/IL-21R fusion gives NK cells sustained cytokine signaling to improve persistence and anti-tumor activity without repeated cytokine dosing.

WNT7B-derived polypeptides promote bone formation and regeneration through Reck/Gpr124/Ca2+/Nfatc1 signaling without classical WNT/β-catenin risks.

Intein-spliced fluorescent biosensors detect hippocalcin in living stem cells, enabling real-time single-cell tracking of neuronal differentiation.

Gene-edited allogeneic T cells remove TCR expression and add immune-evasion features to reduce rejection, graft-versus-host risk, and low persistence.

CD64-targeting CAR T cells attack resistant AML and leukemia stem cells to address venetoclax and azacitidine relapse.

A coiled-coil transmembrane fusion protein forms pseudo-viral particles that standardize allergen display while boosting IgG with low basophil activation.

Engineered miniature CasMINI and guide RNAs solve CRISPR size limits, enabling efficient mammalian editing with AAV-compatible delivery.

A humanized CAR targets the IGLV3-21R110 B-cell receptor to kill CLL cells while sparing healthy B cells and reducing toxicity.

Recombinant BChE-albumin and BChE-Fc fusion proteins replace plasma-derived enzyme supply to scale cancer treatment and lower infection risk.

Modular multivalent protein scaffolds replace complex antibodies to improve tumor diffusion, lower production burden, and speed therapeutic screening.

Modified donor immune cells enriched for Th1 CD4+ cells help resist tumor immunosuppression and improve adoptive cell therapy efficacy.

Microbial expression of mink hair keratins enables scalable fur-like textile materials without the supply limits and ethical issues of natural fur.

Targeting stable CS1 with engineered scFv CAR-T cells helps sustain myeloma killing when BCMA down-regulation limits response.

Novel anti-HER2 CDR variants and CAR constructs target distinct HER2 epitopes to improve killing of trastuzumab-resistant cancer cells.

Small anti-Claudin-6 binders improve tumor penetration while enabling CAR-T targeting of solid tumors linked to drug resistance.